Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuanjie Niu
Observed name:
Yuan-jie Niu
Institutions:
Tianjin Medical University General Hospital,
Second Hospital of Tianjin Medical University,
Tianjin Medical University
Observed institutions:
Tianjin Medical University General Hospital,
Second Hospital of Tianjin Medical University,
Tianjin Medical University
ORCID:
0009-0001-8271-9021
Observed ORCID:
0009-0001-8271-9021
OpenAlex ID:
A5065358711
SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance
2025
·
Guojiang Wei
, Ying Huang
, et al.
·
Cell Death Discovery
·
39
Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer
2017
·
Xiaodong Huo
, Bin Huo
, et al.
·
Journal of Contemporary Brachytherapy
·
31
PDF
Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-κB activation and promotes docetaxel efficacy in prostate cancer
2024
·
Jianpeng Yu
, Minghao Zhang
, et al.
·
Oncogene
·
14
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
·
Clinical Cancer Research
·
12
PDF
Percutaneous computed tomography-guided permanent 125 I implantation as therapy for pulmonary metastasis
2018
·
Xiaodong Huo
, Bin Huo
, et al.
·
Journal of Contemporary Brachytherapy
·
10
PDF
Relationships of dietary habits with prostate cancer risk: results from Mendelian randomization analyses and the National Health and Nutrition Examination Survey
2024
·
Zhen Zhou
, Jin Xu
, et al.
·
Food & Function
·
5
FMNL2/SRC-mediated androgen receptor translocation into the nucleus promotes enzalutamide resistance of prostate cancer
2025
·
Jianpeng Yu
, Yukui Gao
, et al.
·
iScience
·
3
[Undifferentiated prostate sarcoma with cartilage metaplasia: a case report and review of the literature].
2011
·
Jing Chen
, Chang-yi Quan
, et al.
·
PubMed
·
2
Data from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S5 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S4 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Show more works
View as search
Works count:
16
Citation count:
116
H-index:
5
I10-index:
5
Year
Topic
Type